These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34151636)

  • 1. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
    Weaver SB; Rungkitwattanakul D; Singh D
    J Pharm Pract; 2023 Feb; 36(1):139-148. PubMed ID: 34151636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
    Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
    SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
    Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
    Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
    Newman TV; Yang J; Suh K; Jonassaint CR; Kane-Gill SL; Novelli EM
    JAMA Netw Open; 2023 Nov; 6(11):e2344546. PubMed ID: 37991760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
    Migotsky M; Beestrum M; Badawy SM
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
    Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
    Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
    Alkhalifah SA; Alanazi M; Almasaoud MA; Al-Malki HS; Al-Murdhi FM; Al-Hazzaa MS; Al-Mufarrij SM; Albabtain MA; Alshiakh AA; AlRuthia Y
    BMC Emerg Med; 2022 Nov; 22(1):188. PubMed ID: 36447134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease.
    Cieri-Hutcherson NE; Hutcherson TC; Conway-Habes EE; Burns BN; White NA
    Pharmacotherapy; 2019 Nov; 39(11):1095-1104. PubMed ID: 31505045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
    Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
    Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
    Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
    Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.
    Zaidi AU; Glaros AK; Lee S; Wang T; Bhojwani R; Morris E; Donohue B; Paulose J; Iorga ŞR; Nellesen D
    Orphanet J Rare Dis; 2021 Nov; 16(1):460. PubMed ID: 34727959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
    Stevens DL; Hix M; Gildon BL
    J Pharm Technol; 2021 Aug; 37(4):209-215. PubMed ID: 34752581
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of L-Glutamine in reducing the frequency of acute complications among patients with sickle cell disease: A randomized controlled study.
    Ebeid FSE; Aly NH; Shaheen NM; Abdellatif SMA; Okba AAM; Gad NA; Makkeyah SM
    Ann Hematol; 2024 Sep; 103(9):3493-3506. PubMed ID: 39028356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
    Inusa BPD; Mnika K; Babiker S
    Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
    Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
    N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.
    Osunkwo I; Manwani D; Kanter J
    Ther Adv Hematol; 2020; 11():2040620720955000. PubMed ID: 33062233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management.
    Darbari DS; Sheehan VA; Ballas SK
    Eur J Haematol; 2020 Sep; 105(3):237-246. PubMed ID: 32301178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.